EBSEmergent BioSolutions Inc.
$6.81-31% 1Y
$6.81
$4.4552 weeks$13.90
The financials
Emergent BioSolutions Inc. by the numbers
Emergent BioSolutions Inc. (EBS) reported revenue of $234M in Q2 2026 (quarter ended Jun 30, 2026), up 66% from the same quarter a year earlier. That came with a gross margin of 59% and net loss of $180M. For the full year FY2025, revenue was $743M (−29% year on year) and net income $53M. The next results filing is expected around Oct 28, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $234M | $141M | +66% |
| Gross profit | $137M | $74M | +85% |
| Operating income | −$125M | $1.6M | to a loss |
| Net income | −$180M | −$12M | n/a |
| Diluted EPS | −$3.49 | −$0.22 | n/a |
Drug Manufacturers, Specialty & Generic
Ranks #31 of 41 by RyuScore